 |
|
|
| |
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir and ± Ribavirin in Adult Renal or Liver Transplant Recipients With HCV Infection (CORAL-I: Cohorts 3-6)
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Kosh Agarwal1, Robert S Brown, Jr2, Emily O Dumas3, Geoff W McCaughan4, Didier Samuel5, Norah Terrault6, Kimberly A Brown7, Parvez S Mantry8, Marina Berenguer9, Paul Y Kwo10, Jacqueline O'Leary11, Mariem Charafeddine3, Tami Pilot-Mati as3, Diana L Shuster3, Wenjing Lu3, Jeffrey V Enejosa3, Daniel E Cohen3, Zoe Mariño12, Xavier Forns12
1Institute of Liver Studies, Kings College Hospital, London, United Kingdom; 2Weill Cornell Medical College, Center for Liver Disease and Transplantation, New York, New York, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, Australia; 5Hôpital Paul Brousse Centre Hépato-Biliaire, Villejuif, France; 6University of California, San Francisco, San Francisco, California, United States; 7Henry Ford Health System, Detroit, Michigan, United States; 8The Liver Insti tute at Methodist Dallas, Dallas, Texas, United States; 9La Fe University Hospital and Centro de Investi gación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas, Valencia, Spain; 10Stanford University School of Medicine, Palo Alto, California, United States; 11Baylor University Medical Center, Dallas, Texas, United States; 12Liver Unit, Hospital Clinic, IDIBAPS, CIBEREHD, Barcelona University, Barcelona, Spain
|
| |
|
|
|
|
|
